AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Regenxbio's chart shows bullish signals with Bollinger Bands expanding upward.
ByAinvest
Monday, Sep 22, 2025 11:33 am ET1min read
Regenxbio's 15-minute chart exhibits an upward-expanding Bollinger Bands pattern, accompanied by a bullish Marubozu candle at 09/22/2025 11:30. This indicates a dominant market trend driven by buyers, who are exerting control over the market, and suggests a continuation of bullish momentum.
Acadian Asset Management LLC has invested approximately $1.12 million in REGENXBIO Inc. (RGNX), acquiring 157,266 shares during the first quarter, which represents about 0.31% of the company [1]. This investment comes amid a mixed analyst sentiment, with ratings ranging from a "strong sell" to a "buy" rating and target prices between $17.00 and $52.00 [1].The biotechnology company reported a loss of $1.38 EPS for the last quarter, significantly missing consensus estimates, with overall revenue coming in at $21.36 million compared to expected $40.87 million [1]. Despite the earnings miss, REGENXBIO's stock has experienced volatility, trading up 3.7% recently [1].
Analysts have mixed views on REGENXBIO's future prospects. Wall Street Zen cut the stock from a "hold" rating to a "strong sell" rating, while Chardan Capital and HC Wainwright reaffirmed a "buy" rating with price objectives of $52.00 and $34.00, respectively [1]. The consensus rating is "Moderate Buy" with a target price of $28.38 [1].
The 15-minute chart of REGENXBIO's stock exhibits an upward-expanding Bollinger Bands pattern, accompanied by a bullish Marubozu candle at 09/22/2025 11:30. This pattern indicates a dominant market trend driven by buyers, suggesting a continuation of bullish momentum .
Other institutional investors have also shown interest in REGENXBIO. FNY Investment Advisers LLC, Brooklyn Investment Group, Pallas Capital Advisors LLC, Entropy Technologies LP, and ProShare Advisors LLC have purchased new positions or increased their stakes in the company [1].
CEO Curran Simpson sold 7,734 shares of REGENXBIO stock, representing a 3.07% decrease in his position [1]. The company's market cap stands at $449.03 million, with a price-to-earnings ratio of -2.58 and a beta of 1.17 [1].
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet